Repurposing the Thalidomide to the Treatment of Irinotecan-Induced Intestinal Mucositis: An Old Drug to a New Use

Rafaela Miranda Pessoa, William Gustavo Lima, Kátia Duarte Vital, Valbert Nascimento Cardoso and Simone Odília Antunes Fernandes
Additional contact information
William Gustavo Lima: These authors contributed equally.
Simone Odília Antunes Fernandes: Department of Clinical and Toxicological Analyses, University of Minas Gerais, Brazil

Global Journal of Pharmacy & Pharmaceutical Sciences, 2018, vol. 6, issue 2, 33-35

Abstract: Intestinal mucositis (IM) is an inflammation caused by antitumor therapy, it seems as side effect especially in irinotecan-based protocols. This condition has a negative impact on patient’s quality of life and treatment effectiveness, once restricts food intake and may predispose the patient to secondary infections. Currently in the clinical practice, only palliative measures are used to treat the IM, which represent the main clinical limitation in management this condition. In this scenario, the repurposing of compounds that are already in clinical use highlight as a rapid and effective strategy against IM caused by chemotherapy. The use of thalidomide has already been demonstrated as a good therapeutic option in preclinical models of irinotecan-induced IM, due its ability to modulate proinflammatory response and to reduce the levels of enterotoxic metabolite of this antitumor agent (i.e., SN-38). In this sense, thalidomide appears as a promising compound for repositioning the therapy of IM, since it exhibits high clinical efficacy and does not affect the activity of ongoing antitumor treatment.

Keywords: juniper publishers:Journal of Pharmacy; Global Journal of Pharmacy; Pharmaceutical Sciences; Pharmacy & Pharmaceutical Sciences; pharmaceutical sciences journals; omics online; open access; drug discovery; Clinical Trials; juniper publishers open access journals; juniper publishers reivew (search for similar items in EconPapers)
Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/gjpps/pdf/GJPPS.MS.ID.555682.pdf (application/pdf)
https://juniperpublishers.com/gjpps/GJPPS.MS.ID.555682.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jgjpps:v:6:y:2018:i:2:p:33-35

DOI: 10.19080/GJPPS.2018.06.555682

Access Statistics for this article

Global Journal of Pharmacy & Pharmaceutical Sciences is currently edited by Sophia Mathis

More articles in Global Journal of Pharmacy & Pharmaceutical Sciences from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().